SHANGHAI, Sept. 28, 2026 /PRNewswire/ — MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital. The investment marks an important milestone in the company’s development and will support its next phase of global growth.

The fund was jointly established by Cathay Capital, L’Oréal and the Shanghai Jing’an District Government to foster innovation in beauty, health and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare and technology, with notable investments including Moonshot AI (Kimi), autonomous driving company Momenta, U.S. fintech company Chime, digital asset platform Ledger, global delivery platform Glovo and AI biotechnology company Owkin.

In addition to identifying emerging brands, investment platforms of this kind can give strategic partners earlier access to emerging technologies, supply-chain capabilities and innovation in adjacent industries. Cathay Capital’s investment in MOYOM reflects growing interest in technologies and biomaterial innovations with the potential to shape the next generation of the beauty and medical aesthetics industry.

Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite (CaHA) regenerative materials. Its flagship brand, Aphranel^®, brings MOYOM’s proprietary biomaterials research to market. Positioned as a new-generation CaHA biostructurer, Aphranel^® is designed to combine immediate structural support, regenerative stimulation and complete biodegradation.

MOYOM’s technology platform is built around two proprietary technologies: ACD-MT^® raspberry-shaped through-hole CaHA microspheres and PCD-ETT^® physically cross-linked CMC gel technology. Together, they are engineered to deliver structural performance, support regenerative interaction and enable controlled biodegradation.

Aphranel^® received Class III medical device registration from China’s National Medical Products Administration (NMPA) in February 2025 and certification under the European Union Medical Device Regulation (EU MDR) in May 2026, establishing a regulatory foundation for international expansion. Since its commercial launch in May 2025, Aphranel^® has been introduced in more than 700 medical aesthetics clinics across China, demonstrating increasing market adoption alongside continued scientific and regulatory progress.

With its proprietary technology platform, key regulatory milestones and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital’s global ecosystem, the company plans to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets, while continuing to invest in next-generation regenerative biomaterials.

The financing will support MOYOM’s efforts to bring biomaterial innovation originating in China to international markets and establish Aphranel^® as a science-driven regenerative aesthetics brand with global reach.

About MOYOM Biotech

Founded in 2018, MOYOM Biotech develops regenerative aesthetic biomaterials and absorbable implantable medical devices. The company developed Aphranel^®, its flagship CaHA-based regenerative aesthetics brand.

View original content to download multimedia:https://www.prnewswire.com/news-releases/moyom-biotech-secures-financing-from-cathay-capital-to-accelerate-global-growth-in-regenerative-aesthetics-302891333.html

SOURCE MOYOM Biotech